Denali Therapeutics Conference Call Summary Company Overview - **Company**: Denali Therapeutics (NasdaqGS:DNLI) - **Focus**: Development of therapies for neurodegenerative diseases, particularly those involving the central nervous system (CNS) Key Points 2026 as a Pivotal Year - 2026 is highlighted as a significant year for Denali, with the company nearing the first approval of **tividenofusp alfa** for **Hunter syndrome** [12][16] - The company is also advancing its pipeline with new data on the **Sanfilippo program** and plans for new clinical trials in **Alzheimer's** and **Pompe disease** [12][13] Regulatory and Approval Insights - Denali is in the final stages of discussions with the FDA regarding the **PDUFA** date, which has been moved to **April 5, 2026** due to a miscalculation of molecular weight [15][17] - The company expresses confidence in its data and engagement with the FDA, emphasizing the robustness of clinical and biomarker data [16][18] Market Dynamics and Expectations - Denali anticipates a **minimal revenue** in the first year post-launch, focusing instead on patient starts and market penetration [27] - The company views the market as a **switch market**, where newly diagnosed patients will be crucial for growth [27] Product Differentiation - **Tividenofusp alfa** is positioned as a significant advancement over **Elaprase**, with the ability to cross the blood-brain barrier and treat neurological aspects of Hunter syndrome [23][28] - The company aims to maximize efficacy in both peripheral and CNS treatment, addressing neurological symptoms that develop in patients over time [23][29] Pipeline Developments - Denali is also working on the **Sanfilippo** and **Pompe** programs, with plans for a **BLA filing** for Sanfilippo in **2027** [35][36] - The company is exploring dosing regimens for Sanfilippo, finding that weekly dosing is better tolerated than bi-weekly dosing [34] Competitive Landscape - Denali acknowledges the competitive nature of the **TfR-enabled programs** and aims to leverage its engineering capabilities to differentiate its products [14][66] - The company is aware of the growing number of brain shuttle technologies in development and emphasizes the importance of engineering in achieving successful outcomes [66][67] Future Outlook - Denali is preparing for the potential launch of tividenofusp alfa and is actively engaging with the FDA to ensure readiness [68][69] - The company is optimistic about its future pipeline, including ongoing studies in Alzheimer's and the potential for new therapies targeting tau and amyloid [46][59] Conclusion - Denali Therapeutics is positioned for a transformative year in 2026, with significant advancements in its product pipeline and a strong focus on regulatory engagement and market entry strategies. The company aims to lead in the area of blood-brain barrier engineering while addressing critical unmet needs in neurodegenerative diseases.